Skip to main content

Generic Uceris Availability

Last updated on May 11, 2022.

Uceris is a brand name of budesonide, approved by the FDA in the following formulation(s):

UCERIS (budesonide - aerosol, foam;rectal)

  • Manufacturer: SALIX
    Approval date: October 7, 2014
    Strength(s): 2MG/ACTUATION [RLD]

UCERIS (budesonide - tablet, extended release;oral)

  • Manufacturer: SALIX
    Approval date: January 14, 2013
    Strength(s): 9MG [RLD] [AB]

Has a generic version of Uceris been approved?

A generic version of Uceris has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Uceris and have been approved by the FDA:

budesonide tablet, extended release;oral

  • Manufacturer: ACTAVIS LABS FL INC
    Approval date: July 3, 2018
    Strength(s): 9MG [AB]
  • Manufacturer: MYLAN
    Approval date: September 17, 2020
    Strength(s): 9MG [AB]

Note: No generic formulation of the following product is available.

  • budesonide - aerosol, foam;rectal

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Uceris. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Controlled release and taste masking oral pharmaceutical composition
    Patent 10,307,375
    Issued: June 4, 2019
    Assignee(s): COSMO TECHNOLOGIES LIMITED

    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

    Patent expiration dates:

    • September 7, 2031
      ✓ 
      Drug product
  • Patent 10,660,858

    Patent expiration dates:

    • September 7, 2031
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical composition
    Patent 8,895,064
    Issued: November 25, 2014
    Assignee(s): Cosmo Technologies Limited

    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

    Patent expiration dates:

    • September 7, 2031
      ✓ 
      Drug product
  • Controlled release and taste making oral pharmaceutical composition
    Patent 9,132,093
    Issued: September 15, 2015
    Assignee(s): COSMO TECHNOLOGIES LIMITED

    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

    Patent expiration dates:

    • September 7, 2031
      ✓ 
      Drug product
  • Controlled release and taste masking oral pharmaceutical composition
    Patent 9,192,581
    Issued: November 24, 2015
    Assignee(s): COSMO TECHNOLOGIES LIMITED

    Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

    Patent expiration dates:

    • September 7, 2031
      ✓ 
      Patent use: INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
      ✓ 
      Drug product

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.